Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
Joao Pedro FerreiraAbhinav SharmaCyrus MehtaGeorge BakrisPatrick RossignolWilliam B WhiteFaiez ZannadPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2020)
The addition of multi-proteomic biomarkers to a clinical model in this population with diabetes and a recent MI allowed a better risk prediction and event reclassification, potentially helping for better risk assessment and targeted treatment decisions. T2D type 2 diabetes, MI myocardial infarction, CV cardiovascular, HFH heart failure hospitalization, Δ delta, cNRI continuous net reclassification index, BNP brain natriuretic peptide, TRAILR2 trail receptor 2 (or death receptor 5), Gal-9 galectin-9, FGF23 fibroblast growth factor 23.
Keyphrases
- cardiovascular events
- heart failure
- type diabetes
- cardiovascular disease
- risk assessment
- left ventricular
- coronary artery disease
- glycemic control
- clinical trial
- study protocol
- label free
- heavy metals
- atrial fibrillation
- randomized controlled trial
- resting state
- phase iii
- white matter
- cancer therapy
- phase ii
- human health
- acute heart failure
- insulin resistance
- multiple sclerosis
- drug delivery
- metabolic syndrome
- brain injury
- skeletal muscle
- functional connectivity
- open label
- smoking cessation
- cerebral ischemia